Benzinga

Benzinga Japan

Benzinga

Benzinga Japan

Benzinga

Benzinga Japan
金曜日, 9 04

Vertex Pharmaceuticals Inc

VRTXNASDAQ
Trade with Public
Trade with Public
$557.96
1.210.22%
近くで: Sep 3, 5:00 PM EST
$559.00
1.040.19%
時間外: 7:58 PM EST
M&A: Crinetics Pharmaceuticals (CRNX) was acquired by Vertex Pharmaceuticals (VRTX) on Tuesday, September 1, 2026 for $10B paid in cash
概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Vertex Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Vertex Pharmaceuticals (VRTX).

Price Target Range — 7 Quarters

Analyst Consensus — 27 Analysts

21Buy
5Hold
1Sell
Consensus RatingBuy# Analysts27Avg. Consensus PT$542Upside to Avg. PT-3.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Sep 2, 2026Morgan StanleyTerence FlynnReinstatesOverweight$665
Aug 5, 2026Truist SecuritiesDanielle BrillPT RaiseBuy$560→$565
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Morgan Stanley Reinstates Overweight on Vertex Pharmaceuticals, Announces $665 Price Target

Morgan Stanley analyst Terence Flynn reinstates Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and announces $665 price target.
Benzinga Newsdesk

PRO
Live On CNBC, Karen Firestone Announces Bought Vertex Pharmaceuticals

Benzinga Newsdesk

PRO
CNBC Halftime Report Final Trades: ServiceNow, Uber Technologies, Vertex Pharmaceuticals

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $565

Truist Securities analyst Danielle Brill maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $560 to $565.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $617

Barclays analyst Eliana Merle maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $615 to $617.
Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $550

TD Cowen analyst Phil Nadeau maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $525 to $550.
Benzinga Newsdesk

データとAPI: Benzinga API · 株式ニュースAPI · アナリスト評価API · 企業ロゴAPI

市場データ提供元 Benzinga API

Benzinga

Benzinga Japan

ニュース

パートナーシップ

ベンジンガ・グローバル

© 2026 Benzinga | All Rights Reserved